Cargando…

Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis

PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhuoyue, Li, Hui, Kang, Yimin, Liu, Yanlong, Shan, Ligang, Wang, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386738/
https://www.ncbi.nlm.nih.gov/pubmed/35992228
http://dx.doi.org/10.2147/TCRM.S363404
_version_ 1784769878081667072
author Wang, Zhuoyue
Li, Hui
Kang, Yimin
Liu, Yanlong
Shan, Ligang
Wang, Fan
author_facet Wang, Zhuoyue
Li, Hui
Kang, Yimin
Liu, Yanlong
Shan, Ligang
Wang, Fan
author_sort Wang, Zhuoyue
collection PubMed
description PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs with respect to the digestive system. Several meta-analyses have compared the risks of digestive side effects of SSRIs and other antidepressants. We aimed to compare the risks of various SSRIs (fluoxetine, escitalopram, citalopram, paroxetine, and sertraline) for adverse reactions of the digestive system. METHODS: Systematic searches returned 30 randomized controlled trials (n = 5004) of five antidepressants and placebos. RESULTS: Fluoxetine had the lowest probability of digestive side effects, ranking fifth at 0.548. Sertraline had the highest probability of digestive side effects, with a probability of 0.611. For gastrointestinal tolerability, escitalopram was better than paroxetine (odds ratio [OR] =0.62, 95% confidence interval [CI] 0.43–0.87) and sertraline (OR=0.56, 95% CI 0.32–0.99). CONCLUSION: Fluoxetine exhibited distinct advantages compared to other SSRIs, while sertraline had the greatest likelihood of digestive system side effects. These findings will help doctors understand the relative advantages of various antidepressants.
format Online
Article
Text
id pubmed-9386738
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93867382022-08-19 Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis Wang, Zhuoyue Li, Hui Kang, Yimin Liu, Yanlong Shan, Ligang Wang, Fan Ther Clin Risk Manag Review PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs with respect to the digestive system. Several meta-analyses have compared the risks of digestive side effects of SSRIs and other antidepressants. We aimed to compare the risks of various SSRIs (fluoxetine, escitalopram, citalopram, paroxetine, and sertraline) for adverse reactions of the digestive system. METHODS: Systematic searches returned 30 randomized controlled trials (n = 5004) of five antidepressants and placebos. RESULTS: Fluoxetine had the lowest probability of digestive side effects, ranking fifth at 0.548. Sertraline had the highest probability of digestive side effects, with a probability of 0.611. For gastrointestinal tolerability, escitalopram was better than paroxetine (odds ratio [OR] =0.62, 95% confidence interval [CI] 0.43–0.87) and sertraline (OR=0.56, 95% CI 0.32–0.99). CONCLUSION: Fluoxetine exhibited distinct advantages compared to other SSRIs, while sertraline had the greatest likelihood of digestive system side effects. These findings will help doctors understand the relative advantages of various antidepressants. Dove 2022-08-13 /pmc/articles/PMC9386738/ /pubmed/35992228 http://dx.doi.org/10.2147/TCRM.S363404 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Wang, Zhuoyue
Li, Hui
Kang, Yimin
Liu, Yanlong
Shan, Ligang
Wang, Fan
Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
title Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
title_full Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
title_fullStr Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
title_full_unstemmed Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
title_short Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
title_sort risks of digestive system side-effects of selective serotonin reuptake inhibitors in patients with depression: a network meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386738/
https://www.ncbi.nlm.nih.gov/pubmed/35992228
http://dx.doi.org/10.2147/TCRM.S363404
work_keys_str_mv AT wangzhuoyue risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis
AT lihui risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis
AT kangyimin risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis
AT liuyanlong risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis
AT shanligang risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis
AT wangfan risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis